Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator

被引:2
|
作者
Karnam, Ravikiran S. S. [1 ,2 ]
Punchhi, Gopika [1 ,3 ]
Mitsakakis, Nicholas [4 ]
Chen, Shiyi [5 ]
Saracino, Giovanna [6 ]
Lilly, Leslie [1 ,7 ,8 ]
Asrani, Sumeet K. K. [6 ]
Bhat, Mamatha [1 ,7 ,8 ,9 ]
机构
[1] Univ Hlth Network, Ajmera Transplant Program, Toronto, ON, Canada
[2] Narayana Hlth, Bengaluru, India
[3] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[4] Eastern Ontario Res Inst, Childrens Hosp, Ottawa, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Biostat Dept, Toronto, ON, Canada
[6] Baylor Univ, Med Ctr, Dallas, TX USA
[7] Univ Toronto, Dept Med, Div Gastroenterol, Toronto, ON, Canada
[8] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
[9] Univ Toronto, Dept Med, 585 Univ Ave, Toronto, ON, Canada
关键词
liver transplantation; NASH; outcomes; recipient factors; risk score; risk stratification; CRYPTOGENIC CIRRHOSIS; SURVIVAL; DISEASE; MODEL; SCORE; MELD; MORTALITY; UTILITY;
D O I
10.1111/ctr.14930
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundNon-alcoholic Steatohepatitis (NASH) cirrhosis is the second most common indication for liver transplantation (LT) in the US and often is associated with significant co-morbidities. We validated a model and risk prediction score that reflects the benefit derived from LT for NASH cirrhosis by predicting 5-year survival post-LT. MethodsWe developed a prediction score utilizing 6515 NASH deceased donor LT (DDLT) recipients from 2002 to 2019 from the Scientific Registry of Transplant Recipients (SRTR) database to identify a parsimonious set of independent predictors of survival. Coefficients of relevant recipient factors were converted to weighted points to construct a risk scoring system that was then externally validated. ResultsThe final risk score includes the following independent recipient predictors and corresponding points: recipient age (5 points for age >= 70 years), functional status (3 points for total assistance), presence of TIPSS (2 points), hepatic encephalopathy (1 point), serum creatinine (5 points if >1.45 mg/dl), need for mechanical ventilation (3 points), and dialysis within 1 week prior to LT (7 points). Diabetes is a stratifying variable for baseline risk. Scores range from 0 to 20 with scores above 13 having an overall survival of <65% at 5 years post-LT. Internal and external validation indicated good predictive ability. ConclusionOur practically useable and validated risk score helps to identify and stratify candidates who will derive the most long-term benefit from LT for NASH cirrhosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [42] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course
    Cortez-Pinto, H
    Camilo, ME
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1089 - 1104
  • [43] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Klein, Thomas
    Mark, Michael
    DIABETES, 2012, 61 : A265 - A266
  • [44] Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Miele, Luca
    Forgione, Alessandra
    Gasbarrini, Giovanni
    Grieco, Antonio
    TRANSLATIONAL RESEARCH, 2007, 149 (03) : 114 - 125
  • [45] Effects of pentoxifylline and weight reduction on liver histology in patients with non-alcoholic steatohepatitis (NASH)
    Kumar, Ajay
    Kumar, Ashish
    Sakhuja, Puja
    Singh, Deepak K.
    Sharma, Barjesh C.
    Sarin, Shiv K.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S236 - S236
  • [46] The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
    Mehta, Rohini
    Jeiran, Kianoush
    Koenig, Aaron B.
    Otgonsuren, Munkzhul
    Goodman, Zachary
    Baranova, Ancha
    Younossi, Zobair
    BMC MEDICAL GENETICS, 2016, 17
  • [47] Management of patients with non-alcoholic steatohepatitis (NASH) in real life
    Serfaty, Lawrence
    LIVER INTERNATIONAL, 2018, 38 : 52 - 55
  • [48] Role of pioglitazone (PIO) in patients with non-alcoholic steatohepatitis (NASH)
    Belfort, RS
    Harrison, S
    Brown, K
    Darland, C
    Finch, J
    Tio, F
    Gastaldelli, A
    Hardies, J
    Berria, R
    Dwivedi, S
    Havranek, R
    Balas, B
    Fincke, C
    DeFronzo, R
    Cusi, K
    DIABETOLOGIA, 2005, 48 : A280 - A280
  • [49] Non-alcoholic fatty liver disease (NAFLD) recurrence after liver transplant (OLT) for non-alcoholic steatohepatitis(NASH)
    Kawamura, Norio
    Nazzal, Mustafa
    El-Gazzaz, Galal
    Spaggiari, Mario
    Fujiki, Masato
    Diago, Teresa
    Aucejo, Federico N.
    Hashimoto, Koji
    Quintini, Cristiano
    Winans, Charles
    Eghtesad, Bijan
    Miller, Charles M.
    Fung, John J.
    Alkhouri, Naim
    Kelly, Dympna
    HEPATOLOGY, 2014, 60 : 617A - 617A
  • [50] Apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis (NASH)
    Sazci, A.
    Akpinar, G.
    Aygun, C.
    Ergul, E.
    Senturk, O.
    Hulagu, S.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S263 - S263